Archive for December, 2020
WrapTechnologies (NASDAQ:WRAP), an innovator of modern policing solutions, announced that BolaWrap(R), its patented, hand-held remote restraint device, was used by the Virginia Police Department in Minnesota earlier this month. The successful deployment of the revolutionary device was captured on bodycam video footage, which WRAP will release today. The footage will be shown during a live Zoom webinar, slated to begin at 10 a.m. ET; the company will also upload the video to its YouTube channel following the webinar. In addition to the footage, the webinar will feature an overview of the BolaWrap as well as a recorded interview with Virginia Police Department Chief Nicole Young-Mattson.
To attend the webinar, visit http://ibn.fm/hfIsb
To view the full press release, visit http://ibn.fm/f6kC9
About Wrap Technologies Inc.
WRAP is an innovator of modern policing solutions. The company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a distance from 10 to 25 feet. Developed by award-winning inventor Elwood Norris, the company’s chief technology officer, the small but powerful BolaWrap 100 assists law enforcement in safely and effectively deescalating encounters, especially those involving an individual in crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury in a number of cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth and Oak Ridge. For more information about the company, please visit www.WRAP.com.
NOTE TO INVESTORS: The latest news and updates relating to WRAP are available in the company’s newsroom at http://ibn.fm/WRAP
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
VistaGen Therapeutics (NASDAQ: VTGN) has appointed a new vice president of translational medicine. A pioneer in the development of neuroactive steroids known as pherines, Louis Monti, MD., PhD., developed the original scientific platform that enabled the early research and development of VistaGen’s PH94B and PH10. The two intranasal neuroactive steroid drug candidates (pherines) have potential for the rapid-onset treatment of anxiety and depression disorders, respectively. VistaGen is a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. Throughout his career, Monti has researched neuroactive pherines and their potential as a treatment for anxiety and depression. His new role at VistaGen allows him to continue to assist with the late-stage clinical development of PH94B and PH10 as well as employ his impressive R&D background in working with neuroactive steroids to discover expansion opportunities for the company. “We have had the pleasure of working closely with Dr. Monti in a consultative capacity since 2018 to complement our efforts to develop PH94B and PH10 to improve the lives of millions of people worldwide who suffer from anxiety and depression disorders every day,” stated VistaGen CEO Shawn K. Singh in the press release. “As we approach several potentially significant milestones for these differentiated neuropsychiatric drug candidates in 2021 and beyond, Dr. Monti’s unique knowledge, expertise, and insight about their potential, as well as potential opportunities for further expansion of our CNS pipeline, will be valuable. We are excited that he has now joined us as a full-time member of our R&D team.”
To view the full press release, visit http://ibn.fm/YaS3C
About VistaGen Therapeutics Inc.
VistaGen is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information about the company, please visit www.Vistagen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- SGTM engaged Anthony L.G., PLLC to initiate FORM-10 process to become fully reporting, assist with SEC legal issues and uplist to NASDAQ
- SGTM produces environmentally beneficial products using natural waste created by hurricanes and storms while preventing burdens on municipal landfills
- Clients include The Kroger Co., Circle K, 7-Eleven, Menards Inc., Old Castle Lawn & Garden, large retailers and municipalities
- SGTM recorded 794% increase in revenue, 4,817% increase in gross profit for first half of 2020 when compared to all of 2019
Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, has engaged Anthony L.G., PLLC to initiate the FORM-10 process to become fully reporting, assist with all SEC legal matters, and uplist to the NASDAQ. The engagement was made following a highly successful year for the company, marked by a string of lucrative contracts that included agreements with The Kroger Co., Circle K, 7-Eleven, Menards Inc., Old Castle Lawn & Garden, and more.
“We have communicated with many firms since our audit completion to see who would be best suited for our team, shareholders, and to transpire our vision,” said SGTM CEO and Director Tony Raynor. “After communicating with Laura Anthony and doing our due diligence, our team feels more confident than ever on achieving our ultimate goal to be listed on the NASDAQ.”
In preparation for the FORM-10 process, SGTM completed audits for the two years ending December 2018 and 2019 at the end of October this year. Business results for the company have been impressive, resulting primarily from its successful growth strategy based on providing solutions to organic waste burdens created by storms and hurricanes in the United States.
Rather than allow tree debris and other natural waste to burden municipal landfills, SGTM transforms this resource into organic next-generation products that benefit the environment such as garden mulch and certified playground surface material. The company grew significantly in 2020 as a result of new national partnerships, strategic acquisitions and organic growth strategies resulting in new revenue streams and contracts. In anticipation of its future uplisting, the company recently reported remarkable financial results that include a 794% increase in revenue and a massive 4,817% increase in gross profit during the first half of 2020 when compared to all of 2019 (https://ibn.fm/AJBfc).
SGTM offers synergistic solutions that benefit the environment while offering investors an excellent opportunity to purchase shares in a sustainable business with promising growth potential. The importance of ethical investing appears to be trending upwards, evidenced by surveys of millennials that suggest that the majority would accept lower returns if an investment was sustainable (https://ibn.fm/WHuKa). SGTM provides that opportunity, driven forward by its expert management team that continues to fulfill the company mission while expanding operations and diversifying revenue streams amid increased demand for sustainable solutions to serious environmental issues.
To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/YTjPF.
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights to publicly traded companies through Sequire, today announced that it will host the 13th Annual LD Micro Main Event, a prominent two-day virtual investor conference, via its Sequire Virtual Events platform. The event is slated to be held on Dec. 14 – 15, 2020. A leader in influential small- and micro-cap conferences, LD Micro gained access to the largest active base of micro-cap investors in the world at over 2 million and counting with the recent SRAX acquisition. Interested parties may visit https://ibn.fm/kO1Hi to register for the event, which will feature, via an engaging new format, more than 250 presenting companies and several influential panelists. “With the launch of this virtual conference, we are one step closer to our mission of creating the most comprehensive platform for issuers. In collaboration with our partners, we are inviting close to 2M active small-cap investors to the Main Event,” said Christopher Miglino, founder and CEO of SRAX. “We believe this conference will be a success for both the investors and the issuers in the Sequire community, and we look forward to the expansion of the LD Micro audience.”
To view the full press release, visit http://ibn.fm/GgIN9
About SRAX Inc.
SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and MySequire.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Biotech stocks and penny stocks go hand-in-hand in many ways. One of the clearest is how speculation tends to drive momentum. Much like penny stocks, traders speculate on what potential outcomes may be during different phase trials that companies conduct. Furthermore, much like penny stocks, biotech stocks have a tendency to overreact on news days. This goes for both moves higher and lower.
This leads me to a big point, which is to pay attention to what companies discuss. That also goes for times when bad news hits. There may be short-term pain in lieu of a longer-term potential gain. It’s also important to consider that some biotech stocks will surge during the days leading up to a data date. They then can sell off once the news is released. Biotech stocks are well-known for the “buy the rumor, sell the news” type of trend. The name of the game here is to be on the right side of the move. Understanding all of these type of catalysts can help you make money with penny stocks, instead of holding a bag.
Now that the COVID headline has calmed down a bit, traders are now looking for more traditional biotech news. The long and short of it is that COVID may have introduced millions of new traders to the potential of biotech and now we’re seeing a fresh group of individuals interested in profiting from this volatile sector. Due to this, will any of these biotech penny stocks be on your list heading into December?
Biotech Stocks To Watch
- Auris Medical Holding Ltd. (EARS Stock Report)
- Predictive Oncology Inc. (POAI Stock Report)
- Catabasis Pharmaceuticals (CATB Stock Report)
- Mustang Bio Inc. (MBIO Stock Report)
Biotech Penny Stocks To Buy [or sell]: Auris Medical Holding Ltd.
Auris Medical Holding Ltd. is one of the biggest gainers of December 1st. During early trading on Tuesday, shares of EARS stock shot up by as much as 324%. In the past month, shares are up by almost 500%. So what is driving this massive bull run for EARS stock? Well, as a clinical-stage company working on therapeutics, Auris has been able to receive a critical appeal for meeting the needs of otherwise unmet areas of the healthcare sector.
On December 1st, the company announced that its substance AM-301, has shown a great deal of efficacy in protecting against Covid-19 infections. AM-301, which is a nasal spray, reduced viral titer by as much as 92.4% compared to a placebo.
“We are very excited to see the protective effects of AM-301 against Sars-CoV-2 confirmed in an assay that very closely replicates real-life conditions in the human nose. Our first experiments in September showed that AM-301s key component trapped up to 99% of Sars-CoV-2 when brought into contact with a viral suspension. Now, with our newly developed spray formulation, we have direct evidence that AM-301 has the potential to significantly mitigate the risk of infection of nasal mucosal cells.”
Thomas Meyer, the founder, and CEO of Auris
As a covid related penny stock, Auris Medical Holdings looks like it could have a lot of potentials if things continue to go well for it. With this in mind, Auris Medical could remain a penny stock to watch for the near term.
Biotech Penny Stocks To Buy [or sell]: Predictive Oncology Inc.
Predictive Oncology Inc. has begun building some momentum during the last few weeks. Most recently, POAI stock has jumped a bit more after reporting a strong, year-over-year EPS growth. In its previous Q3 2019 report, EPS came in at a loss per share of $1.31. This year, the loss was 46 cents per share. While sales were lower, year over year, the company’s discussion on upcoming milestones and current initiatives seems ot have sparked renewed interest.
“Management continues to focus the majority of its resources on the Company’s primary mission of applying artificial intelligence to precision medicine and to drug discovery. Our approach and the mediums used to replace rats and mice in preliminary cancer studies are working in three of our operating subsidiaries, Helomics, TumorGenesis and Soluble Biotech.”
Dr. Carl Schwartz, Predictive Oncology CEO
Right now traders are monitoring the company for its expected completion of a Helomics Magee study. Helomics applies artificial intelligence to its rich data gathered from patient tumors to personalize cancer therapies for patients and drive the development of new targeted therapies.
Biotech Penny Stocks To Buy [or sell]: Catabasis Pharmaceuticals
Catabasis Pharmaceuticals is another one of the penny stocks that has been climbing for the last month or so. After dropping from levels above $6 in October, CATB stock has followed a slow and steady uptrend from $1.25 to recent highs of $1.75 this month.
Read More
As I said above, it’s about what managed says after both good and bad results. In this case, Catabasis reported that its Phase 3 PolarisDMD trial of its edasalonexent treatment for Duchenne muscular dystrophy missed its primary endpoint. As a result, the comapny said it was stopping activities related to the development of edasalonexent. Catabasis’ plan was to work with advisors to evaluate alternatives. The company engaged Ladenburg Thalmann & Co. Inc. to act as its strategic financial advisor.
“Potential strategic options that may be evaluated include a merger, business combination, in-licensing, out-licensing or other strategic transaction.”
As we saw earlier this week with certain companies taking up a similar platform, though it took time, many ended up coming out stronger. Will that be the case for Catabasis?
Biotech Penny Stocks To Buy [or sell]: Mustang Bio Inc.
Mustang Bio Inc. has been a force to reckon with during the month of November and now into December. Since November 2nd, MBIO stock has climbed from around $2.70 to highs this week of $3.85. A lot of that momentum stemmed from strong earnings as well as new agreements. There was also an apparent speculative build-up to the company’s upcoming key opinion leader call later this month.
First, the company and Minaris Regenerative Medicine GmbH announced an agreement to enable technology transfer and GMP clinical manufacturing of Mustang’s MB-107 lentiviral gene therapy program. This is for the treatment of X-linked severe combined immunodeficiency also known as bubble boy disease, in Europe. Minaris is a leading contract development and manufacturing service provider for the cell and gene therapy industry.
Following this, Mustang received a long-awaited opinion from the European Medicines Agency on the Orphan Drug Designation of lentriviral for bubble boy disease. The Designation applies to MB-107 for the treatment of newly diagnosed infants between two months and two years of age. It also applies to to MB-207 for the treatment of patients who have been previously treated with hematopoietic stem cell transplantation and for whom re-treatment is indicated.
This week interim Phase 1/2 data on Mustang Bio’s MB-106, a CAR-T cell therapy for patients with certain non-Hodgkin lymphomas, will be presented at the ASH meeting.
The past decade has seen great advancements in automobile technology. Tesla showed that electric vehicles were a viable transportation option, and in the decade since the firm launched its first electric vehicle (“EV”), the industry has come a long way. Now, we aren’t just talking about electric vehicles, we are also seeing firms develop autonomous, self-driving vehicles. And thanks to two new programs approved by the California Public Utilities Commission (“CPUC”), people in California will soon be able to ride in a self-driving “robotaxi.”
For quite a while, the Sunshine state has been familiar with self-driving vehicles, with the CPUC approving more than a dozen companies’ requests to test out their self-driving vehicles on the streets of California. However, these firms were not allowed to launch commercial ride-hailing services using their autonomous vehicles, partly due to California’s strict rules for autonomous vehicle operators. In fact, the state has the most strict regulations in the entire country, requiring AV operators to obtain different licenses for different types of testing, list the number of miles driven, divulge any vehicle crashes as well as the number of times human safety drivers had to take control of the autonomous vehicles.
The California Public Utilities Commission, which regulates autonomous vehicles (“AVs”) and taxis in fleet service functions such as ride-hailing, has been hard at work on the rules that will regulate a commercial ride-hailing service for AVs for a number of years. The result of these efforts was two programs: DAV, or the Drivered Autonomous Vehicle Program, and the Driverless Autonomous Vehicle Deployment Program. According to CPUC, these two programs will allow AV operators that opt in to avail passenger services, shared rides, as well as to accept payment for the use of the vehicles.
CPUC Commissioner Genevieve Shiroma says that the two programs will be case studies in how autonomous vehicles can enhance the state’s efforts to electrify the streets. In addition, California Governor Gavin Newsom recently announced that the state will ban the sale of new fossil-fuel-powered automobiles by 2035, a move that puts the state in line with countries such as the UK, Norway, Sweden and Iceland.
AV operators that would like to opt into the two programs are required to obtain a charter-party carrier Class P permit or Class A charter-party certificate in the Drivered AV Passenger Service’s pilot program from the CPUC together with an AV testing permit from California’s DoV. Participating firms will also be expected to hand in quarterly reports to the regulator containing aggregated data about the pick-up as well as drop-off points, how many wheelchair-accessible AVs, the fuel types and electric-charging vehicles used, how many miles vehicles and passengers have traveled, and service to disadvantaged communities.
Elsewhere in the country, there is a flurry of activity in the EV sector. For example, Net Element (NASDAQ: NETE) revealed its intention to merge with an electric carmaker called Mullen Technologies, Inc. It should be remembered that Net Element is a financial tech company, so it will be interesting to see how the new entity created pans out.
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, on Monday announced its commencement of clinical trial site recruitment for its upcoming Acclaim-1 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). The company’s timing of patient recruitment and enrollment keeps it on track for its Acclaim-1 clinical trial to commence in the first-half of 2021. “Our clinical team is engaging with prestigious cancer centers and research institutions across the U.S. to ensure we select optimal study sites, which play an important role in the success of a clinical trial,” said Rodney Varner, president and chief executive officer of Genprex. “We look forward to working with leading clinical investigators who will help drive our mission to bring forth a treatment for advanced lung cancer patients.”
To view the full press release, visit http://ibn.fm/zxX8J
About Genprex Inc.
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s web site atwww.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- Financial report notes working capital of $44.7 million at end of Q3 2020, increase of 17% over Q2 2020
- Key quarter highlights include becoming debt-free, progress on rare earth elements (“REEs”)
- CEO reports company making “significant strides in the last quarter on our uranium, rare earths and other initiatives”
Energy Fuels (NYSE American: UUUU) (TSX: EFR) has released its financial results for the quarter ended Sept. 30, 2020, as well as a corporate update (https://ibn.fm/dZn68). In addition to being debt free, the report noted that the company had working capital of $44.7 million at the end of Q3 2020, which is an increase of 17% over Q2 2020. The working capital included $28.1 million in cash and marketable securities, plus $25.6 million of concentrate inventory and work in progress. Following the end of the quarter, the company retired all of its outstanding debt.
Another key quarter highlight for Energy Fuels includes being selected by the U.S. Department of Energy (“DOE”) to develop a design for the production of a rare earth element (“REE”) concentrate from coal-based resources. The company will work with a team from Penn State University on the project. Energy Fuels’ management team anticipates that the REEs contained in these coal-based resources are similar to the REEs contained in other ores it is currently evaluating in its REE program.
“Energy Fuels made significant strides in the last quarter on our uranium, rare earths and other initiatives,” said Energy Fuels president and CEO Mark S. Chalmers. “On the uranium front, we were pleased to see the U.S. Department of Commerce successfully extend the Russian Suspension Agreement. . . On the REE front, we are making excellent progress. We are currently conducting pilot-scale testing on ore sources at the White Mesa Mill, which is confirming our ability to produce an on-spec rare earth concentrate at a commercial level, along with the uranium from the ore. We are also in discussions with various parties in North America regarding rare earth/uranium ore sources for the Mill and potential purchase of our finished rare earth concentrate.”
As Chalmers mentioned, in September, the U.S. Department of Commerce announced it had obtained Russia’s agreement to extend limits on uranium imports into the United States. The extended Russian Suspension Agreement (“RSA”) was finalized in October. The expiration of the RSA, originally scheduled for the end of 2020, could have resulted in unlimited quantities of Russian uranium imports into the United States. The extension of the limits provides long-term support of the U.S. uranium mining industry.
Energy Fuels’ ability to achieve a debt-free status marks a significant accomplishment (https://ibn.fm/0huC3). “While many uranium and other natural resource companies have significant debt burdens, Energy Fuels is proud to announce that today we became debt free,” said Chalmers. “Being debt-free distinguishes Energy Fuels not only from many of our peers in the uranium and natural resource sectors but also from many public companies in general. Having no debt reduces costs and allows Energy Fuels to better weather market volatility. Coupled with our strong working capital position, this also provides us with a ‘clean slate’ from which to increase uranium production when warranted and to launch the exciting rare earth element initiative we are pursuing. We have a number of opportunities in front of us right now, any one of which could result in significant cash flows for the company.”
Energy Fuels is the number-one U.S. producer of uranium. The company was also the top U.S. producer of vanadium in 2019 and is conducting pilot-scale testing to potentially begin producing a rare earth element concentrate at its White Mesa Mill as soon as Q1-2021. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today. The Nichols Ranch ISR Project is fully licensed, constructed and on standby, and licensed to produce 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also fully licensed, constructed and on standby, and licensed to produce 1.5 million pounds of U3O8 per year.
For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
- Biotechnology developer CNS Pharmaceuticals is preparing, with its partner WPD Pharmaceuticals, a global set of Phase 2 trials for its drug candidate Berubicin, which has shown promise in combating the effectively fatal glioblastoma multiforme (“GBM”) brain cancer
- Since another company conducted Phase 1 safety trials for Berubicin 14 years ago, one patient has survived cancer-free while two others saw reductions in tumor size of up to 80 percent
- The Phase 2 trials will build on the Phase 1 results, conducting targeted testing that offers side-by-side comparison between Berubicin and chemotherapy drug lomustine in real time beginning next year
- The company is also preparing with WPD to conduct the first Phase I trials of Berubicin in children in Europe
- CNS Pharmaceuticals officers recently participated virtually in the annual Society for Neuro-Oncology (“SNO”) Scientific Meeting and Education Day to promote their work and discuss the progress of clinical trials
While the world’s attention remains occupied with developments related to the global coronavirus pandemic that has infected about 60 million people and claimed the life of nearly 1.5 million of them (https://ibn.fm/ki9Vf), a dedicated group of researchers continues to pursue breakthroughs on the nearly always fatal glioblastoma multiforme (“GBM”) type of brain cancer. Recently, the Society for Neuro-Oncology (“SNO”) held its 25th Annual Scientific Meeting and Education Day to spotlight the efforts of over 2,600 researchers and clinician scientists from more than 40 countries in researching and treating GBM and similar brain cancers (https://ibn.fm/WCLpE).
CNS Pharmaceuticals (NASDAQ: CNSP) appeared at the virtual conference through a joint sponsorship with WPD Pharmaceuticals, staffing a booth in the virtual exhibit hall while Dr. Patrick Wen, a member of CNS’s Science Advisory Board, participated in a panel discussion on clinical trials during the plenary session Nov. 20, and in online poster presentations throughout the three-day event (https://ibn.fm/L99MV).
CNS Pharmaceuticals is preparing to launch a Phase 2 trial of its leading drug candidate, Berubicin, an anthracycline that has demonstrated significant potential in appearing to effectively cross the blood-brain barrier and effectively targeting central nervous system malignancies.
The medical science companies presenting their progress toward a more effective treatment of glioblastomas at the SNO conference generally focused on the safety and tolerability of using their drug candidates in animals or early-stage human trials. CNS appears to have an advantage in that Berubicin not only demonstrated safety in the Phase 1 trials conducted by another company 14 years ago; the clinical benefit response of stable disease or better was 44 percent with one patient who still remains alive and cancer-free and another two patients whose tumors shrunk by up to 80 percent.
CNS has obtained Orphan Drug Designation (“ODD”) for Berubicin in treating malignant gliomas and announced Nov. 17 that it has now filed an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) which has been accepted for review (https://ibn.fm/C99tn).
The company’s Phase 2 trial will recruit 243 patients for side-by-side, real-time analysis of Berubicin’s performance against the chemotherapy standard of care drug lomustine. The trials will take place on a global scale, administering Berubicin to 162 tumor patients and Iomustine to the other 81 in about 60 study centers scattered across North America, Europe and the Asia-Pacific region, company officers said in a November webinar (https://ibn.fm/pbPBn).
“We are evaluating responses defined as a decrease in the size of the tumor, as well as stability of the disease defined as no further increases in the size of the tumor once the patient is put on study, as well as the time to progression of these tumors and importantly overall survival of the patients,” CMO Dr. Sandra Silberman said during the webinar.
Existing treatments mostly avail themselves of surgery and the drug temozolomide, which has been shown effective in temporarily extending the lifespan of fewer than 40 percent of GBM patients with a specific genetic variation. But overall, glioblastoma patients have a median survival rate of only 14.6 months from the date of the malignancy’s diagnosis as the cancer recurs and resists new interventions — a significant reason why the Berubicin trial participant’s survival for 14 years without cancer is so exciting.
CNS expects the trial enrollment to take two to two and a half years with funding occurring in stages as critical benchmarks are achieved. CEO John Climaco said the trial could potentially lead Berubicin toward an expedited regulatory pathway, which would save time and money in the long run.
CNS is also simultaneously pursuing a first-ever Phase I Berubicin safety trial in Poland for children who have the GBM tumor and have run out of other medical options. This trial is being conducted by WPD Pharmaceuticals, a CNS sub-licensee.
For more information, visit the company’s website at www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
If you’ve ever had to get a scan to assess for head trauma, then you probably had an MRI. The immobile and costly procedure is also used to detect brain cancer. To help make this diagnostic option more accessible, a group of scientists led by researchers from the Massachusetts General Hospital has created a portable, compact, low-cost MRI scanner.
This scanner can be located in a doctor’s office or small clinics or installed in an ambulance. The portability of this power head only scanner also allows it to be wheeled into the ward or a patient’s room. This innovation was reported in a research that was published in the “Nature Biomedical Engineering” journal.
Clarissa Zimmerman Cooley, the study’s lead author, explains that while the MRI is the leading imaging technique used for brain imaging, acquiring and installing a regular MRI scanner is not only difficult but also expensive. The author is a researcher at the Athinoula A. Martinos Center for Biomedical Imaging in Radiology at the Massachusetts General Hospital. She explains that in some cases, even when MRI scanners are available, it may be dangerous or difficult to move a patient to the scanner suites. She cites this as a major motivation behind the need to make the MRI more accessible.
Together with her colleagues, Cooley developed and examined the prototype MRI scanner for a brain scan. This prototype is plugged into an electrical outlet and creates much less noise in comparison with the conventional MRI scanner. This small MRI scanner’s magnet is said to be roughly the size of a laundry hamper and weighs 230 kg, which is roughly 500 pounds. This weight is inclusive of its cart, console, amplifiers, coils and magnet. The scanner’s cart can be pushed around from one place to another by one person. Additionally, its total weight can be reduced by about 70 kg, to about 350 pounds if some of its equipment is replaced with efficient and custom lightweight designs.
The researchers conducted tests on three healthy adult volunteers. They discovered that the scanner produced 3D brain images in roughly 10 minutes.
Cooley states that this technology may extend the MRI’s reach, adding that when developed further, it may allow scanning in remote locations, particularly in places where MRIs have not been available, as well as imaging for patients by the bedside.
Still on the subject of the brain, another company making a remarkable contribution is the biotech firm CNS Pharmaceuticals Inc. (NASDAQ: CNSP). Its singular focus is on finding new remedies to cancers that affect not only the brain but also the central nervous system.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Blue Hat Interactive (NASDAQ: BHAT), a leading producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China, has signed a definitive agreement for the acquisition of 51% of Fuzhou Csfctech Co. Ltd. The agreement also includes Csfctech’s two subsidiaries. A developer and distributor of mobile games in China, Csfctech offers more than 100 games on several platforms. The company has an operation center in mainland China and an international user base across mainland China, Japan, Taiwan, the United Arab Emirates and Africa. The acquisition is expected to close by the end of the year. “This is a milestone agreement for Blue Hat, and we are pleased to move forward with the official signing of the definitive agreement,” said Blue Hat CEO Xiaodong Chen in the press release. “This will broaden our interactive gaming portfolio and allow our Company to increase sales even further through the expansion of available distribution platforms. We were extremely diligent in working to move forward on this acquisition throughout a challenging 2020, and by the end of the year expect to close and acquire a company that will greatly strengthen our mobile games business under favorable terms in both valuation and performance incentives. We feel that the benefits of our combined companies will help to drive greater brand awareness for Blue Hat and each of our lines of business in mobile games, AR toys and AR education.”
To view the full press release, visit https://ibn.fm/vvhE6
About Blue Hat Interactive Entertainment Technology
Blue Hat Interactive is a producer, developer and operator of AR interactive entertainment games and toys in China , including interactive educational materials, mobile games, and toys with mobile game features. The company’s interactive entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information about the company, please visit https://ir.BlueHatGroup.com/investor-relations.
NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
